Business Context and Reporting Period
This Form 6-K filing covers the month of November 2006 for Sanofi-Aventis, a foreign private issuer headquartered in Paris, France. The report serves to incorporate by reference three press releases issued during the period regarding regulatory approvals, vaccine shipments, and government contracts.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing designed to disclose material non-financial events rather than report quarterly or annual financial performance.
Material Changes and Operational Updates
- Pediatric Exclusivity: On November 29, 2006, Sanofi-Aventis received pediatric exclusivity for Ambien and Ambien CR, extending market protection for these products.
- Influenza Vaccine Shipment: On November 27, 2006, Sanofi Pasteur completed the shipment of 50 million doses of influenza vaccine.
- H5N1 Pre-Pandemic Contract: On November 20, 2006, Sanofi Pasteur signed a contract with the U.S. Government to stockpile a new type of H5N1 pre-pandemic vaccine.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the operational updates provided in the attached press releases. No unusual items or contingencies are detailed in the text of the Form 6-K itself.
Investor Verification Checklist
- Verify the commercial impact and duration of the pediatric exclusivity granted for Ambien and Ambien CR.
- Confirm the revenue recognition timeline associated with the 50 million influenza vaccine doses shipped.
- Review the specific terms, volume, and pricing of the H5N1 pre-pandemic vaccine contract with the U.S. Government.
- Check subsequent filings for financial results reflecting these operational milestones.